Abstract
Physostigmine, advocated in the treatment of Alzheimer's disease, was incorporated in various o/w emulsions in an attempt to achieve a slow release preparation with improved bioavailability. Despite the use of different oil types, no significant improvement was attained in the awake rat model. Furthermore, increasing the viscosity by adding sodium alginate and increasing the phospholipid concentration in the emulsion failed to retain physostigmine under perfect sink conditions as confirmed by the in vitro and in vivo results. Further studies are being carried out to improve the current formulation.
Original language | English |
---|---|
Pages (from-to) | 163-169 |
Number of pages | 7 |
Journal | S.T.P. Pharma Sciences |
Volume | 3 |
Issue number | 2 |
State | Published - 1993 |
Keywords
- Alzheimer's disease
- cholinesterase inhibition
- in vitro release
- physostigmine salicylate
- submicron emulsions